Investigating how type 2 immune responses affect pancreatic cancer growth
Role of type 2 immune response in pancreatic cancer tumorigenesis
This study is looking at how certain immune responses might affect the growth of a tough type of pancreatic cancer, and it aims to find new treatment options that could help patients by focusing on the way cancer cells and immune cells work together.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10866515 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of type 2 immune responses in the development of pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer. The study explores how specific immune cells and cytokines in the tumor microenvironment contribute to tumor growth and resistance to treatment. By examining the interactions between cancer cells and immune cells, particularly the influence of cytokines like IL4, IL13, and IL33, the research aims to identify new therapeutic strategies that could improve patient outcomes. Patients may be involved in trials that test new treatments targeting these immune interactions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those who have not responded well to existing treatments.
Not a fit: Patients with other types of cancer or those who are not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates for patients with pancreatic cancer.
How similar studies have performed: Other research has shown promise in targeting immune responses in cancer treatment, suggesting that this approach could lead to meaningful advancements.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Dey, Prasenjit — Roswell Park Cancer Institute Corp
- Study coordinator: Dey, Prasenjit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.